AstronauTx launches to target astrocytes for Alzheimer's

AstronauTx is looking to go beyond the amyloid/tau paradigm in Alzheimer's disease with £6.5 million ($7.8 million) in seed capital to develop therapies that modulate

Read the full 256 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE